Watts R G, Ben-Ari E T, Bernstein L R, Birrer M J, Winterstein D, Wendel E, Colburn N H
Laboratory of Viral Carcinogenesis, NCI, FCRDC, Frederick, MD 21702, USA.
Mol Carcinog. 1995 May;13(1):27-36. doi: 10.1002/mc.2940130106.
Tumor promoters such as 12-O-tetradecanoylphorbol-13-acetate (TPA) and epidermal growth factor (EGF) induce neoplastic transformation, elevated c-jun protein expression, and activator protein-1 (AP-1)-dependent gene expression in JB6 mouse epidermal cells sensitive to tumor promoters (clone 415a P+ cells). In contrast, JB6 cells resistant to tumor promoter-induced transformation (clone 307b P- cells) exhibit a greatly reduced TPA or EGF inducible c-jun expression and AP-1 activity. We have recently shown that induced AP-1 is necessary for tumor promoter-induced transformation of P+ cells because introduction of a dominant negative c-jun mutant into P+ cells inhibits both AP-1 dependent transactivation and the transformation response to tumor promoter. The intent of the investigation presented here was to test the hypothesis that elevation of AP-1 activity is sufficient to cause progression to the P+ phenotype in P- cells or to the transformed phenotype in P+ cells. Clonally derived P+ and P- recipient cells transfected with a human c-jun expression construct and overexpressing c-jun protein were tested for progression by assaying for constitutive or inducible anchorage independent phenotype and nude-mouse tumorigenicity. Overexpression of c-jun did not produce progression in P- cells but did increase the probability of progression in P+ cells (two of five transfectant cell lines progressed to the tumor phenotype). In addition, c-jun overexpression did not increase AP-1 activity in any of the P-/c-jun transfectants or in the two of five P+/c-jun transfectants that acquired the transformed phenotype. The P+/c-jun transfectants that showed elevated AP-1 activity did not progress to the tumor phenotype, demonstrating that an increase in AP-1 activity is insufficient for this progression. Since P(+)-to-tumor phenotype progression occurred in cells overexpressing c-jun but not AP-1, we propose that P(+)-to-transformed phenotype progression is c-jun dependent and AP-1 independent.
肿瘤促进剂,如12 - O - 十四烷酰佛波醇 - 13 - 乙酸酯(TPA)和表皮生长因子(EGF),可在对肿瘤促进剂敏感的JB6小鼠表皮细胞(克隆415a P +细胞)中诱导肿瘤转化、c - jun蛋白表达升高以及激活蛋白 - 1(AP - 1)依赖性基因表达。相比之下,对肿瘤促进剂诱导的转化具有抗性的JB6细胞(克隆307b P -细胞)表现出TPA或EGF诱导的c - jun表达和AP - 1活性大大降低。我们最近表明,诱导的AP - 1对于肿瘤促进剂诱导的P +细胞转化是必需的,因为将显性负性c - jun突变体引入P +细胞会抑制AP - 1依赖性反式激活以及对肿瘤促进剂的转化反应。本文所述研究的目的是检验以下假设:AP - 1活性的升高足以使P -细胞进展为P +表型或使P +细胞进展为转化表型。通过检测组成型或诱导型非锚定依赖性表型和裸鼠致瘤性,对用人类c - jun表达构建体转染并过表达c - jun蛋白的克隆衍生的P +和P -受体细胞进行进展测试。c - jun的过表达在P -细胞中未产生进展,但确实增加了P +细胞进展的可能性(五个转染细胞系中有两个进展为肿瘤表型)。此外,c - jun过表达在任何P - / c - jun转染细胞或五个获得转化表型的P + / c - jun转染细胞中的两个中均未增加AP - 1活性。显示AP - 1活性升高的P + / c - jun转染细胞未进展为肿瘤表型,表明AP - 1活性的增加不足以导致这种进展。由于P( + )到肿瘤表型的进展发生在过表达c - jun但未过表达AP - 1的细胞中,我们提出P( + )到转化表型的进展是c - jun依赖性的且是AP - 1非依赖性的。